H.C. Wainwright analyst Raghuram Selvaraju adjusted the firm’s price target on Santhera Pharmaceuticals to CHF 24 from CHF 4 and keeps a Buy rating on the shares following the 1-for-10 reverse stock split.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>